USP Acquires Stratix Labs to Boost Microbiology Solutions
New products will enhance existing microbiology offerings and integrate innovative contamination control strategies.
Today, the U.S. Pharmacopeia (USP) announced an important acquisition: Stratix Labs, a technology firm known for its microbiology innovations. This strategic move is set to strengthen USP’s portfolio by expanding its microbiological solutions that aid in the control of microbial contamination across various applications in the pharmaceutical sector, including biologics and compounded medications.
The significance of microbiological quality control cannot be overstated, as it plays a crucial role in ensuring effective contamination control during pharmaceutical manufacturing. As demand in the industry surges, there has been a pressing need for the implementation of new quality control strategies, especially for sterile products. By acquiring Stratix Labs, USP is poised to enhance the capabilities of drug manufacturers and compounding entities in addressing microbial contamination issues, ensuring product safety for patients.
Fouad Atouf, Ph.D., Senior Vice President of Global Biologics for USP, expressed enthusiasm for this acquisition, stating, "This is an exciting moment for USP as we continue to develop and deliver the latest standards and solutions to meet the needs of the industry today and help ensure quality at every stage of pharmaceutical manufacturing and compounding. Through the acquisition of Stratix Labs, USP reaffirms its commitment to pioneering innovation in quality control and upholding its legacy of providing science-based standards for pharmaceutical producers."
The inclusion of Stratix Labs into USP’s operations enables the extension of solutions designed to mitigate microbial contamination risks. This will provide customers with important access to advanced microbiological control testing materials that complement USP’s collection of documentary standards. The revolutionary microbial preservation technology created by Stratix Labs will serve broad applications in the pharmaceutical and biopharmaceutical spaces.
Mark Mulvahill, Co-Founder and CEO of Stratix Labs, commented on the acquisition, stating, "Today's acquisition underscores Stratix Labs' leadership in microbiological quality control and the importance of the technology we have meticulously developed over the years." Furthermore, Josh Erickson, Co-Founder and Chief Technology Officer, emphasized that joining forces with USP will enhance their ability to deliver cutting-edge solutions to USP's clients, including drug manufacturers and compounding entities, creating a new suite of reference materials that will benefit the industry for years to come.
With this acquisition, USP is set to provide innovative, reproducible, and user-friendly materials for microbiological quality control. This development will give customers a comprehensive array of solutions that harmonize with USP's established documentary and reference standards, ultimately helping ensure that safe and high-quality medicines become available to patients more quickly.
Ronald T. Piervincenzi, Ph.D., CEO of USP, added, "The products from Stratix Labs, combined with our existing compendial standards and expertise, will greatly improve the microbial contamination control processes, thereby advancing regulatory confidence in drug safety and quality."
As part of this acquisition, USP will also introduce Enverify™, a solution aimed at bridging a prominent gap in the industry regarding competency in surface testing techniques and recovery methods.
USP has a rich history of over 200 years in evaluating and incorporating new and evolving technologies to ensure its compendium delivers solutions that guarantee the safety and quality of pharmaceuticals. This acquisition marks a pivotal step in that ongoing commitment to quality in pharmaceuticals.
About USP
USP is an independent scientific non-profit organization dedicated to working with top global experts in health and science to produce quality resources and standards for medicines, dietary supplements, and food ingredients. The organization actively collaborates with academic institutions, industry leaders, and regulatory bodies to foster the adoption of advanced manufacturing technologies. Through its wide array of resources, standards, advocacy, and educational initiatives, USP strives to enhance the accessibility of high-quality medicines, supplements, and foods for billions worldwide.
Frequently Asked Questions
What is the significance of USP's acquisition of Stratix Labs?
This acquisition allows USP to expand its microbiology offerings and enhance contamination control measures within pharmaceutical production.
How does this acquisition benefit drug manufacturers?
By integrating Stratix Labs' technologies, drug manufacturers will have improved tools for microbial contamination control, thus ensuring product safety.
What innovative solutions will USP offer after this acquisition?
USP will introduce Enverify™, a solution focused on competency in surface testing techniques and recovery, among other microbiology quality control materials.
How long has USP been evaluating new technologies?
USP has a history spanning over 200 years in assessing and implementing cutting-edge technologies for pharmaceutical quality assurance.
What does USP aim to achieve with this expansion?
USP aims to ensure that high-quality and safe medicines reach patients promptly by enhancing its quality control solutions for the industry.
